{"Symbol": "APLS", "AssetType": "Common Stock", "Name": "Apellis Pharmaceuticals Inc", "Description": "Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.", "CIK": "1492422", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "100 FIFTH AVENUE, WALTHAM, MA, UNITED STATES, 02451", "OfficialSite": "https://apellis.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "2745597000", "EBITDA": "82083000", "PERatio": "60.28", "PEGRatio": "None", "BookValue": "3.171", "DividendPerShare": "None", "DividendYield": "None", "EPS": "0.36", "RevenuePerShareTTM": "8.09", "ProfitMargin": "0.0443", "OperatingMarginTTM": "0.487", "ReturnOnAssetsTTM": "0.0513", "ReturnOnEquityTTM": "0.141", "RevenueTTM": "1016397000", "GrossProfitTTM": "605049000", "DilutedEPSTTM": "0.36", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "1.33", "AnalystTargetPrice": "33.95", "AnalystRatingStrongBuy": "3", "AnalystRatingBuy": "11", "AnalystRatingHold": "7", "AnalystRatingSell": "1", "AnalystRatingStrongSell": "0", "TrailingPE": "60.28", "ForwardPE": "46.3", "PriceToSalesRatioTTM": "2.701", "PriceToBookRatio": "6.84", "EVToRevenue": "2.698", "EVToEBITDA": "29.36", "Beta": "0.239", "52WeekHigh": "30.48", "52WeekLow": "16.1", "50DayMovingAverage": "23.48", "200DayMovingAverage": "22.22", "SharesOutstanding": "126525000", "SharesFloat": "89353000", "PercentInsiders": "13.930", "PercentInstitutions": "101.810", "DividendDate": "None", "ExDividendDate": "None"}